Skip to main content
Premium Trial:

Request an Annual Quote

Nucleai, Sirona Dx Partner on Cancer Biomarker Discovery

NEW YORK – Spatial biology firm Nucleai has partnered with contract research organization Sirona Dx on the discovery of novel biomarkers in solid tumors, the companies said on Wednesday.

Through the deal, the companies will combine Nucleai's artificial intelligence-based spatial analytics platform with Sirona Dx's multiplex assay development know-how to identify novel spatial signatures in high-plex assays that predict response to therapy and guide treatment decisions.

Diagnostic algorithms that result from the alliance can be used to support clinical studies by biopharmaceutical clients, the firms said.

"Multiplex imaging technologies have improved rapidly over the years … [but] identifying actionable insights from all the data collected remains immensely challenging," Nucleai Cofounder and CEO Avi Veidman said in a statement. "This powerful synergy between Sirona Dx and Nucleai is very exciting as it will allow us to identify actionable spatial signatures that can predict response to immunotherapy."

In March, Chicago-based Nucleai, which also maintains operations in Israel, raised $33 million in Series B financing. Around that time, Portland, Oregon-based Sirona Dx struck a comarketing alliance for tissue-based spatial multiplexed immunophenotyping technology with Ultivue.

The Scan

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.

Study Reviews Family, Provider Responses to Rapid Whole-Genome Sequencing Follow-up

Investigators identified in the European Journal of Human Genetics variable follow-up practices after rapid whole-genome sequencing.

BMI-Related Variants Show Age-Related Stability in UK Biobank Participants

Researchers followed body mass index variant stability with genomic structural equation modeling and genome-wide association studies of 40- to 72-year olds in PLOS Genetics.

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.